Two days before ADA 2026: Novo's CagriSema and zenagamtide slate, Structure's oral aleniglipron, an EPFL cyclic-peptide advance, and the field preview.
Read digest →A STAT/Undark BPC-157 evidence probe, an MC4R-deficiency GLP-1 comparison, Sapience's lucicebtide ASCO data, the ADA 2026 preview, and Camurus' June 10 PDUFA.
Read digest →ASCO's biggest peptide-oncology day: Bicycle, Mayo TPIV200, Avacta and Pfizer sigvotatug, plus Syneron's $150M peptide raise and Lilly's ADA slate.
Read digest →Orforglipron maintains weight loss after switching off injectables, Perspective's lead-212 radioligands and BioVaxys' survivin vaccine reach ASCO, BriaCell raises $4.7M.
Read digest →ASCO Day 2 + EASL close: Immutep eftilagimod 7.7-month survival gain, ImPact padeliporfin pancreatic Phase 1, EASL HBV functional-cure late-breakers, copper-peptide cosmetics.
Read digest →ASCO opens + EASL closes: Corbus CRB-701 42.9% OPSCC, Telix ProstACT PSMA, MetaVia DA-1726 9.1% weight loss, BriaCell CAML biomarker, Aligos HBV, GLP-1 breast cancer.
Read digest →EASL Day 2: pemvidutide 48-week oral data, survodutide NEJM MASH 47-62%, Aligos ALG-055009 46% liver fat, Mayo folate-receptor vaccine TNBC, Roswell GLP-1 breast cancer.
Read digest →EASL Day 1: pemvidutide qFibrosis LBP-036, DA-1726 48 mg, ARO-INHBE 44% liver fat, ESSENCE Japanese/menopausal, Rezdiffra Day 1, NeoVax GBM, Aktis AKY-2519.
Read digest →ASCO GLP-1 cancer metastasis 12,112 patients, Oorja Bio launch ORJ-001 IPF, Altimmune Best of EASL pemvidutide, ASCO press briefing 3:30 PM ET, Zealand Pharma EGM.
Read digest →Gilead's Hepcludex (bulevirtide) FDA accelerated approval — first US treatment for chronic HDV, Altimmune pemvidutide EASL fibrosis regression, Madrigal Rezdiffra portal hypertension.
Read digest →Wegovy HD 7.2 mg CHMP positive opinion, Foundayo Week 6 IQVIA ~17K vs Wegovy pill ~142K, ASCO May 26 embargoed press briefing, Memorial Day dual-meeting week.
Read digest →Sapience lucicebtide GBM ASCO, Leerink/RBC TRIUMPH-1 weekend commentary, Corbus CRB-701 Nectin-4, Anglia Ruskin 90K-patient GLP-1 CV meta-analysis, EASL preview.
Read digest →Wegovy pill EU CHMP positive opinion, retatrutide TRIUMPH-1 analyst dysesthesia signal, Bicycle Duravelo-2 Phase 2 65% ORR, Hims $350M convertible, BriaCell 16.6mo OS.
Read digest →Retatrutide TRIUMPH-1 Phase 3 hits 28.3% weight loss + 30.3% extension, ASCO 2026 abstracts release, Regeneron-Parabilis $2.325B Helicon deal, AMAZE-12 amycretin Phase 3.
Read digest →Novo Nordisk pre-EASL ESSENCE liver safety, Parabilis IPO for zolucatetide, 20n Bio cyclic peptide AI, 5W AI citation index, CAMPER anti-MRSA peptide.
Read digest →Ozari Health telehealth $86/mo, Avacta AVA6103 FOCUS-01 Phase 1, MetaVia DA-1726 ADA, PCAC Feb 2027, TerminaTOR mTORC1, chiral peptide-drug conjugates.
Read digest →Novo international Wegovy pill expansion as US scripts cross 2M, BriaCell Bria-OVA+ ovarian pipeline, Tsinghua NK2R AI competition, Aivocode CAQK, Fibulin-4.
Read digest →Wegovy pill scripts decline for first time, Foundayo Week 5 +40%, Lilly analyst targets, Nature Biotech TCR PRP paper, retatrutide TRIUMPH timing, ASCO 2026.
Read digest →